CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis…
MSN,
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update On July 15, 2022, ContraFect Corp.
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update On July 15, 2022, ContraFect Corp.
By: GlobenewsWire - 13 Aug 2021 Multiple peer-reviewed journal publications and presentations at scientific forums drive value…
Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the…
YONKERS, N.Y., Aug. 13, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology…